InMed Closes Over-Subscribed C$9.4 Million Financing

InMed Pharmaceuticals, Inc. (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, has closed its previously announced non-brokered private placement for gross proceeds of C$9.4 Million through the issuance of 13,428,571 units ("Units"), with terms as previously announced on December 18, 2017. The original offering anticipated gross proceeds of C$2.5 Million.  

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S.

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.

GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors

GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members. Joining the Board of Directors today are Catherine Mackey, Alicia Secor and Lord William Waldegrave.

Reliq Health Technologies Announces New Contract with Texas, USA Based Chronic Care Management Provider Serving 1,000 Complex Continuing Care Patients

Reliq Health Technologies Inc. (TSXV:RHT) or (OTCQB:RQHTF), a technology company focused on developing innovative mobile health (mHealth) and telemedicine solutions for Community-Based Healthcare, is pleased to announce that it has signed an agreement with B Golden Care Services, LLC in McAllen, Texas to implement Reliq's iUGO Care chronic care management platform for its 1,000 complex continuing care patients. Onboarding of patients is expected to begin in late Q1 2018.

Isodiol International Inc. Announces Binding Agreement to Acquire Biosynthesis Pharma Group

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has entered into a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp, it's derivatives and pharmaceutical compounds for use in the medicinal, nutraceutical, food and cosmetic industries.

GW Pharmaceuticals Reacquires Full Rights to Develop and Commercialize Sativex® in U.S.

GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces the termination of its previous license agreement with Otsuka Pharmaceutical Co., Ltd. in relation to Sativex® (nabiximols) in the U.S. As a result, GW has now reacquired full ownership of the development and commercialization rights to the product in the U.S.

Pages